Gudas Lab

Publications

Found 8 results
Filters: First Letter Of Title is P  [Clear All Filters]
2022
Del Aguila EMere, Tang X-H, Gudas LJ.  2022.  Pancreatic Ductal Adenocarcinoma: New Insights into the Actions of Vitamin A.. Oncol Res Treat.
2013
Benoit YD, Witherspoon MS, Laursen KB, Guezguez A, Beauséjour M, Beaulieu J-F, Lipkin SM, Gudas LJ.  2013.  Pharmacological inhibition of polycomb repressive complex-2 activity induces apoptosis in human colon cancer stem cells.. Exp Cell Res. 319(10):1463-70.
Laursen KB, Mongan NP, Zhuang Y, Ng MM, Benoit YD, Gudas LJ.  2013.  Polycomb recruitment attenuates retinoic acid-induced transcription of the bivalent NR2F1 gene.. Nucleic Acids Res. 41(13):6430-43.
2012
Benoit YD, Lepage MB, Khalfaoui T, Tremblay E, Basora N, Carrier JC, Gudas LJ, Beaulieu J-F.  2012.  Polycomb repressive complex 2 impedes intestinal cell terminal differentiation.. J Cell Sci. 125(Pt 14):3454-63.
2010
David KA, Mongan NP, Smith C, Gudas LJ, Nanus DM.  2010.  Phase I trial of ATRA-IV and Depakote in patients with advanced solid tumor malignancies.. Cancer Biol Ther. 9(9):678-84.
2007
Boorjian SA, Milowsky MI, Kaplan J, Albert M, Cobham MVallee, Coll DM, Mongan NP, Shelton G, Petrylak D, Gudas LJ et al..  2007.  Phase 1/2 clinical trial of interferon alpha2b and weekly liposome-encapsulated all-trans retinoic acid in patients with advanced renal cell carcinoma.. J Immunother. 30(6):655-62.
2006
Mongan NP, Martin KM, Gudas LJ.  2006.  The putative human stem cell marker, Rex-1 (Zfp42): structural classification and expression in normal human epithelial and carcinoma cell cultures.. Mol Carcinog. 45(12):887-900.
2002
Goldberg JS, Vargas M, Rosmarin AS, Milowsky MI, Papanicoloau N, Gudas LJ, Shelton G, Feit K, Petrylak D, Nanus DM.  2002.  Phase I trial of interferon alpha2b and liposome-encapsulated all-trans retinoic acid in the treatment of patients with advanced renal cell carcinoma.. Cancer. 95(6):1220-7.